MTOR and Iron deficiency anemia: On contrary, low-grade inflammation and the use of mammalian target of rapamycin (mTOR) inhibitors promote the upregulation of hepcidin, leading to reduced iron availability (functional iron deficiency) for erythropoiesis.17